| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE37721 | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct, 2016
(7 years ago) | |
| USRE42461 | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5846966 | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Sep, 2013
(10 years ago) | |
|
US5846966 (Pediatric) | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Mar, 2014
(10 years ago) | |
|
USRE37721 (Pediatric) | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr, 2017
(7 years ago) | |
|
USRE42461 (Pediatric) | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr, 2017
(7 years ago) | |
Vytorin is owned by Organon.
Vytorin contains Ezetimibe; Simvastatin.
Vytorin has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Vytorin are:
- US5846966
- US5846966*PED
- USRE37721*PED
- USRE42461*PED
- USRE37721
- USRE42461
Vytorin was authorised for market use on 23 July, 2004.
Vytorin is available in tablet;oral dosage forms.
Vytorin can be used as to reduce plasma cholesterol levels in a mammal, treatment of primary hypercholesterolemia, mixed hyperlipidemia and/or homozygous familial hypercholesterolemia (hofh).
The generics of Vytorin are possible to be released after 25 April, 2017.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Dec 05, 2011 |
| M(M-109) | Jan 24, 2015 |
Drugs and Companies using EZETIMIBE; SIMVASTATIN ingredient
Market Authorisation Date: 23 July, 2004
Treatment: Treatment of primary hypercholesterolemia, mixed hyperlipidemia and/or homozygous familial hypercholesterolemia (hofh); To reduce plasma cholesterol levels in a mammal
Dosage: TABLET;ORAL
VYTORIN family patents
